Galectin Therapeutics (GALT) Competitors

$2.36 +0.13 (+5.83%)

As of 03:51 PM Eastern

GALT vs. ZVRA, CRMD, PRTA, CYRX, and ANL

Should you buy Galectin Therapeutics stock or one of its competitors? MarketBeat compares Galectin Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Galectin Therapeutics include Zevra Therapeutics (ZVRA), CorMedix (CRMD), Prothena (PRTA), CryoPort (CYRX), and Adlai Nortye (ANL). These companies are all part of the "pharmaceutical products" industry.

How does Galectin Therapeutics compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

In the previous week, Zevra Therapeutics had 19 more articles in the media than Galectin Therapeutics. MarketBeat recorded 22 mentions for Zevra Therapeutics and 3 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.63 beat Zevra Therapeutics' score of 0.46 indicating that Galectin Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Galectin Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zevra Therapeutics has a net margin of 101.58% compared to Galectin Therapeutics' net margin of 0.00%. Zevra Therapeutics' return on equity of 51.49% beat Galectin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Galectin Therapeutics	N/A	N/A	-214.23%

Zevra Therapeutics presently has a consensus price target of $23.33, suggesting a potential upside of 97.16%. Galectin Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 362.18%. Given Galectin Therapeutics' higher probable upside, analysts clearly believe Galectin Therapeutics is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Zevra Therapeutics has higher revenue and earnings than Galectin Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	6.57	$83.23M	$1.99	5.95
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.48	N/A

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by insiders. Comparatively, 52.6% of Galectin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Zevra Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market.

Summary

Zevra Therapeutics beats Galectin Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Galectin Therapeutics compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

In the previous week, CorMedix had 7 more articles in the media than Galectin Therapeutics. MarketBeat recorded 10 mentions for CorMedix and 3 mentions for Galectin Therapeutics. CorMedix's average media sentiment score of 0.63 equaled Galectin Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Galectin Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

34.2% of CorMedix shares are held by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are held by institutional investors. 3.5% of CorMedix shares are held by insiders. Comparatively, 52.6% of Galectin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

CorMedix has a net margin of 52.31% compared to Galectin Therapeutics' net margin of 0.00%. CorMedix's return on equity of 52.30% beat Galectin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	52.31%	52.30%	29.46%
Galectin Therapeutics	N/A	N/A	-214.23%

CorMedix has higher revenue and earnings than Galectin Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	2.04	$163.05M	$2.00	4.05
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.48	N/A

CorMedix presently has a consensus price target of $15.00, suggesting a potential upside of 85.28%. Galectin Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 362.18%. Given Galectin Therapeutics' higher possible upside, analysts clearly believe Galectin Therapeutics is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

CorMedix has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market.

Summary

CorMedix beats Galectin Therapeutics on 12 of the 14 factors compared between the two stocks.

How does Galectin Therapeutics compare to Prothena?

Prothena (NASDAQ:PRTA) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

In the previous week, Prothena had 16 more articles in the media than Galectin Therapeutics. MarketBeat recorded 19 mentions for Prothena and 3 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.63 beat Prothena's score of -0.08 indicating that Galectin Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	0 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Galectin Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.1% of Prothena shares are held by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are held by institutional investors. 10.4% of Prothena shares are held by insiders. Comparatively, 52.6% of Galectin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Galectin Therapeutics has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Galectin Therapeutics' return on equity of 0.00% beat Prothena's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-260.92%	-43.44%	-36.87%
Galectin Therapeutics	N/A	N/A	-214.23%

Galectin Therapeutics has lower revenue, but higher earnings than Prothena. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	52.86	-$244.09M	-$2.82	N/A
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.48	N/A

Prothena presently has a consensus price target of $21.78, suggesting a potential upside of 122.81%. Galectin Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 362.18%. Given Galectin Therapeutics' higher possible upside, analysts clearly believe Galectin Therapeutics is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.36
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Prothena has a beta of -0.23, meaning that its stock price is 123% less volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market.

Summary

Prothena and Galectin Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Galectin Therapeutics compare to CryoPort?

Galectin Therapeutics (NASDAQ:GALT) and CryoPort (NASDAQ:CYRX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

Galectin Therapeutics has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market. Comparatively, CryoPort has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market.

CryoPort has higher revenue and earnings than Galectin Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.48	N/A
CryoPort	$182.94M	3.63	$78.30M	$1.35	9.77

CryoPort has a net margin of 41.57% compared to Galectin Therapeutics' net margin of 0.00%. Galectin Therapeutics' return on equity of 0.00% beat CryoPort's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-214.23%
CryoPort	41.57%	-7.92%	-4.79%

11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of CryoPort shares are owned by institutional investors. 52.6% of Galectin Therapeutics shares are owned by company insiders. Comparatively, 10.0% of CryoPort shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Galectin Therapeutics currently has a consensus price target of $11.00, suggesting a potential upside of 362.18%. CryoPort has a consensus price target of $14.44, suggesting a potential upside of 9.51%. Given Galectin Therapeutics' higher possible upside, equities analysts clearly believe Galectin Therapeutics is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CryoPort	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

In the previous week, CryoPort had 1 more articles in the media than Galectin Therapeutics. MarketBeat recorded 4 mentions for CryoPort and 3 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.63 beat CryoPort's score of 0.47 indicating that Galectin Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galectin Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CryoPort	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

CryoPort beats Galectin Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Galectin Therapeutics compare to Adlai Nortye?

Galectin Therapeutics (NASDAQ:GALT) and Adlai Nortye (NASDAQ:ANL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

Galectin Therapeutics has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market. Comparatively, Adlai Nortye has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market.

In the previous week, Galectin Therapeutics had 2 more articles in the media than Adlai Nortye. MarketBeat recorded 3 mentions for Galectin Therapeutics and 1 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.94 beat Galectin Therapeutics' score of 0.63 indicating that Adlai Nortye is being referred to more favorably in the news media.

Company	Overall Sentiment
Galectin Therapeutics	Positive
Adlai Nortye	Positive

Galectin Therapeutics currently has a consensus price target of $11.00, suggesting a potential upside of 362.18%. Adlai Nortye has a consensus price target of $21.50, suggesting a potential upside of 54.97%. Given Galectin Therapeutics' higher possible upside, equities analysts clearly believe Galectin Therapeutics is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Galectin Therapeutics has higher earnings, but lower revenue than Adlai Nortye.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.48	N/A
Adlai Nortye	$5M	110.99	-$35.53M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-214.23%
Adlai Nortye	N/A	N/A	N/A

11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are owned by institutional investors. 52.6% of Galectin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Adlai Nortye beats Galectin Therapeutics on 7 of the 11 factors compared between the two stocks.

Get Galectin Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GALT vs. The Competition

Export

Metric	Galectin Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$156.68M	$3.04B	$6.29B	$12.46B
Dividend Yield	N/A	1.96%	2.79%	5.30%
P/E Ratio	-4.96	18.81	20.85	25.56
Price / Sales	N/A	279.58	543.57	72.25
Price / Cash	N/A	56.53	42.94	55.34
Price / Book	-1.20	4.36	9.87	6.72
Net Income	-$30.84M	$72.19M	$3.55B	$333.62M
7 Day Performance	12.80%	-0.61%	-0.23%	0.35%
1 Month Performance	-3.64%	0.34%	1.47%	4.00%
1 Year Performance	83.08%	46.24%	41.05%	36.32%

Galectin Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GALT Galectin Therapeutics	1.7952 of 5 stars	$2.36 +5.8%	$11.00 +366.1%	+68.9%	$155.36M	N/A	N/A	9	News Coverage Upcoming Earnings
ZVRA Zevra Therapeutics	4.0295 of 5 stars	$10.45 +4.0%	$23.00 +120.0%	+41.3%	$610.18M	$106.47M	7.76	20	Analyst Revision
CRMD CorMedix	3.0098 of 5 stars	$7.76 -1.8%	$15.00 +93.3%	-35.5%	$609.87M	$311.71M	3.89	30	News Coverage Earnings Report Options Volume Gap Up
PRTA Prothena	1.9775 of 5 stars	$11.11 +2.9%	$21.67 +95.1%	+26.5%	$599.24M	$9.68M	N/A	130	Earnings Report Analyst Revision
CYRX CryoPort	3.419 of 5 stars	$12.30 +20.5%	$14.79 +20.2%	+89.8%	$591.63M	$176.18M	8.93	1,186	Analyst Upgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GALT) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Galectin Therapeutics (GALT) Competitors

GALT vs. ZVRA, CRMD, PRTA, CYRX, and ANL

How does Galectin Therapeutics compare to Zevra Therapeutics?

Summary

How does Galectin Therapeutics compare to CorMedix?

Summary

How does Galectin Therapeutics compare to Prothena?

Summary

How does Galectin Therapeutics compare to CryoPort?

Summary

How does Galectin Therapeutics compare to Adlai Nortye?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT vs. The Competition

Galectin Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Galectin Therapeutics (GALT) Competitors

GALT vs. ZVRA, CRMD, PRTA, CYRX, and ANL

How does Galectin Therapeutics compare to Zevra Therapeutics?

Does the media prefer ZVRA or GALT?

Is ZVRA or GALT more profitable?

Do analysts rate ZVRA or GALT?

Which has higher valuation and earnings, ZVRA or GALT?

Do institutionals & insiders have more ownership in ZVRA or GALT?

Which has more risk and volatility, ZVRA or GALT?

Summary

How does Galectin Therapeutics compare to CorMedix?

Does the media favor CRMD or GALT?

Do insiders and institutionals have more ownership in CRMD or GALT?

Is CRMD or GALT more profitable?

Which has better valuation & earnings, CRMD or GALT?

Do analysts rate CRMD or GALT?

Which has more volatility & risk, CRMD or GALT?

Summary

How does Galectin Therapeutics compare to Prothena?

Does the media favor PRTA or GALT?

Do insiders and institutionals have more ownership in PRTA or GALT?

Is PRTA or GALT more profitable?

Which has better valuation & earnings, PRTA or GALT?

Do analysts rate PRTA or GALT?

Which has more volatility & risk, PRTA or GALT?

Summary

How does Galectin Therapeutics compare to CryoPort?

Which has more risk and volatility, GALT or CYRX?

Which has stronger earnings and valuation, GALT or CYRX?

Is GALT or CYRX more profitable?

Do institutionals and insiders hold more shares of GALT or CYRX?

Do analysts prefer GALT or CYRX?

Does the media refer more to GALT or CYRX?

Summary

How does Galectin Therapeutics compare to Adlai Nortye?

Which has more risk and volatility, GALT or ANL?

Does the media refer more to GALT or ANL?

Do analysts prefer GALT or ANL?

Which has stronger earnings and valuation, GALT or ANL?

Is GALT or ANL more profitable?

Do institutionals and insiders hold more shares of GALT or ANL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT vs. The Competition

Galectin Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools